Literature DB >> 27914728

Nanotechnology, a new paradigm in atherosclerosis treatment.

Virna M Martín Giménez1, María Belén Ruiz-Roso2, Alejandra Beatriz Camargo3, Diego Kassuha1, Walter Manucha4.   

Abstract

Atherosclerosis, a known and prevalent disease, causes progressive deterioration of affected vessels, inducing a blood flow reduction with different complications, and its symptoms usually manifest in advanced stages of the disease. Therefore, the classic therapeutic alternatives are insufficient because the damages are many times irreversible. For this reason, there is a need to implement intelligent forms of drug administration and develop new therapeutic targets that reduce the progression of atherosclerotic lesion. The implementation of new tools for prevention, diagnosis and treatment of this cardiovascular disease is of special interest, focusing our attention on achieving a more effective control of the immune system. Finally, this review highlights the latest knowledge about nanotechnology as a powerful, modern, and promising therapeutic alternative applied to atherosclerotic disease, as well as warning of the potential complications with their use.
Copyright © 2016 Sociedad Española de Arteriosclerosis. Publicado por Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Alternativas terapéuticas; Aterosclerosis; Atherosclerosis; Diagnosis; Diagnóstico; Nanotechnology; Nanotecnología; Therapeutic alternatives; Tratamiento; Treatment

Mesh:

Year:  2016        PMID: 27914728     DOI: 10.1016/j.arteri.2016.09.002

Source DB:  PubMed          Journal:  Clin Investig Arterioscler        ISSN: 0214-9168


  2 in total

Review 1.  Anandamide and endocannabinoid system: an attractive therapeutic approach for cardiovascular disease.

Authors:  Virna Margarita Martín Giménez; Sandra Edith Noriega; Diego Enrique Kassuha; Lucía Beatriz Fuentes; Walter Manucha
Journal:  Ther Adv Cardiovasc Dis       Date:  2018-05-16

Review 2.  Lipid-based gene delivery to macrophage mitochondria for atherosclerosis therapy.

Authors:  Felix H Zakirov; Dongwei Zhang; Andrey V Grechko; Wei-Kai Wu; Anastasia V Poznyak; Alexander N Orekhov
Journal:  Pharmacol Res Perspect       Date:  2020-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.